CHDI
Dotmatics Has Licensed Its Browser and Vortex Solutions to CHDI
Bishop’s Stortford, UK – Dotmatics Limited (Dotmatics), a leading provider of drug discovery informatics products and services, is pleased to announce they have been selected by CHDI Foundation, Inc (CHDI) to provide scientific data management, data mining, and analysis solutions (Browser), and chemically aware data visualisation software (Vortex) for CHDI’s drug discovery research teams.
Alexander Borchers, Director, Informatics at CHDI said: “After evaluating a number of web-based data mining and analysis products, we found Dotmatics Browser and Vortex the clear leaders in terms of flexibility, performance, and intuitiveness for the end user. Dotmatics’ level of technical support during the pilot testing stage and subsequent deployment to a production system was superior.”
Steve Gallagher, CEO at Dotmatics, said: “We are excited to be working with CHDI to provide solutions for both their data querying and visualisation requirements. Our products are an excellent fit for their collaborative environment.”
Dotmatics’ solutions have provided the following advantages to CHDI:
- Web-based solutions that require minimal set up, zero-client install and low ongoing IT support.
- Easy to use interfaces that scientists can use with minimal training.
- Powerful querying and browsing allows real-time access to the most recent research information.
- Visualisation with built-in chemistry structure depiction and searching, allows superior quality charting and analysis.
About Dotmatics
Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, browsed, managed and shared within companies. Dotmatics has significant expertise in cheminformatics techniques including chemical databases, SAR analysis, data management and data visualization. For further information please visit www.dotmatics.com.
About CHDI
CHDI is a non-profit organization with a mission to rapidly discover and develop drugs that slow the progression of Huntington’s disease. CHDI supports an international network of research laboratories from academia and industry pursuing novel therapies for the treatment of Huntington’s disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. More information about CHDI can be found at www.chdifoundation.org.
About Huntington’s Disease
Huntington’s disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent with a mutation in the huntingtin gene has a 50-50 chance of inheriting the mutation. As a result of carrying the mutation, an individual’s brain cells fail and die leading to cognitive and physical impairments that, over the course of the disease, significantly impair the individual’s
quality of life and ultimately cause death. Symptoms of Huntington’s disease, which generally develop in midlife and become progressively more debilitating as time passes, can also develop in infancy or old age. Once overt symptoms start, patients live for about 15 to 20 years. One person in 10,000 is believed to carry a mutation in the huntingtin gene. There is currently no way to delay the onset of symptoms or slow the progression of Huntington’s disease.